Drug Innovation: Providing More Disease Prevention and Control

"National Safe Drug Month" is being carried out in various places, one of the important contents of this year's event is "to publicize the latest technical achievements in the field of medicine and health, to enhance public understanding of modern medical science and technology, to guide industry enterprises to strengthen independent innovation, and to promote the transformation of scientific and technological achievements to benefit public health." In this regard, The director of pharmacy department of Dalian City Hospital in Liaoning Province, Zhang Shihong, for example, said with emotion: "Clinically used for heart disease more and more new drugs, from a single antihypertensive drug to a long compound antihypertensive drug, from ordinary tablets to slow release preparations, patients are more and more selective." "In fact, this is closely related to the country's policy support and the independent innovation practices of scientific research institutions and enterprises.the production of innovative scientific and technological achievementsProfessor Du Guanhua of the Institute of Pharmaceutical Research of the Chinese Academy of Medical Sciences said that in recent years, the state has increased the efforts to create new drugs, scientific research institutions, enterprises on the research and development of new drugs, investment is also increasing, showing a good momentum of developmentThe Outline of the National Medium- and Long-Term Science and Technology Development Plan (2006-2020) has deployed 16 major scientific and technological projects, of which "major new drug creation" has been progressing smoothly since its inception in 2008, which has played an important role in promoting the strategic transformation of China's pharmaceutical industry from imitation-oriented to independent innovation-oriented, providing support for service medical reform and safeguarding people's livelihood.held a press conference in early August this year, the National Health and Family Planning Commission, Deputy Director of the Department of Science and Education Wang Chen introduced: major new drug creation special highlights the demand-orientedSuch as for major diseases, developed a number of high-quality and low-cost new drugs, a total of 82 new drug certificates, 118 clinical approvals, in some areas to break the monopoly of foreign drug market or fill the domestic gapAt the same time, more than 15.3 percent of the country's basic drugs have been technically modified, effectively improving the quality of medicines and reducing production costs, providing a guarantee for the implementation of the basic drug systemSubsequently, in 2014, the annual meeting of Chinese pharmaceutical entrepreneurs, the national "12th Five-Year Plan" major new drug creation special technical general manager Sang Guowei also revealed: as of last year, "12th Five-Year Plan" "major new drug creation special has been harvested 34 new drug certificates, 52 varieties." Chemical drugs, biological drugs, traditional Chinese medicine has completed a large number of large varieties of technical transformation.the "major new drug creation" special output, not only mobilize the enthusiasm of research and development, but also improve the research and development capacityDu Guanhua said: "From the people's point of view, the biggest benefit is the original treatment of drugs, now have better drugs, and the original disease sedatives, now there are treatment drugs." Du Guanhua to stroke treatment for example, the original in addition to thrombotic drugs, there is no suitable drugs in the international community, and now we have developed butyl peptides, dansin polyphenols, ginkgo diazepam and other innovative drugs, so that stroke treatment has more drug options.long-term clinical work in the cardiovascular Zhang Shihong also for example, Alisatan ester tablets as a domestic blood pressure reduction new drugs, antihypertensive effect is strong, early effect, in different treatment times of lower ingenuity consistency is better, less volatility, in the clinical also provides patients with a choice.In order to better maintain and promote public health, the Drug Review Centre of the State Administration of Food and Drug Administration is also improving the efficiency and quality of the review, focusing on addressing unmet clinical needs and the availability and affordability of public drug useIn 2013, the approval of paramevir sodium chloride injections in the field of anti-infective drugs, and the approval of Independently innovative chinese drugs such as Compaxip eye injections in ophthalmology, providing the possibility for patients to obtain the latest treatment sprees.enterprises independent innovation into the climaxDu Guanhua said that at present, pharmaceutical enterprises are gradually becoming the main body to undertake major special tasks, the emergence of a number of innovative drugs, to a certain extent, reflects the enterprise's independent innovation ability is growing.'s introduction of DrLi Hexin, Vice President of Research and Development of Green Leaf Pharmaceutical Group, also confirms this: Green Leaf insists on investing 7% of its sales revenue into new drug research and development each year and continuously increasing, providing a strong guarantee for the construction of a scientific and technological innovation system In the research and development of new drug preparations, the focus is on the establishment of long-acting slow-release microspheres, injection liposomes and other release system technology platform, research and improve the evaluation methods and indicators of new drug-administration system technology, plans to launch the United States, the European Union and other new drugs with China's independent intellectual property rights At present, there are 22 new drug projects, mainly related to clinically important and major diseases, such as memory impairment, Parkinson's disease, schizophrenia, diabetes, tumors, etc , of which 4 independent research and development products in the United States to carry out registered clinical research. the results are confirmed by Sang Guowei said: In the past five years, China's pharmaceutical industry products growth rate of 20.1%, higher than the national industrial average of 4.5 percentage points In 2008, when the "major new drug creation special" started, there were only two enterprises with major revenues of more than 10 billion yuan, and by June this year, the number of enterprises with revenues of 10 billion yuan had reached 11, of which two had crossed the 40 billion yuan mark And from the beginning of August, the Health and Family Planning Commission held a press conference to send out the message is also exciting: "11th Five-Year Plan period, by the enterprise-led declaration to undertake the major new drug creation special project reached 34.9%;" Since the implementation of the 12th Five-Year Plan, it has grown to 52.8% Under the impetus of "major new drug creation special", many enterprises have strengthened the construction of research and development centers, strengthened cooperation with research institutes and universities, and played an important role in improving the innovation ability of China's pharmaceutical industry. " we have been working with the Chinese Academy of Medical Sciences, China Pharmaceutical University, Shandong University, China Ocean University and other institutions to actively promote innovative drug research and development It is worth mentioning that in early 2001 we and Yantai University each invested 50% of the yantai University School of Pharmacy, creating a pharmaceutical enterprises combined with the new drug research and development model Li said. " At present, the internationalization process of medicine in China is also developing rapidly In the United States, tamcmo, ramotridine and other chemical preparations through the FDA certification and sales in the United States, Chinese medicine products such as compound dansin drop pills, blood lipid capsules, positive capsules, heart lotus tablets and other important varieties to complete phase II clinical Under the two-wheel drive to strengthen the national industrial policy support and enterprise's willingness to actively explore the international market, more and more enterprises and more products will enter the international market Liu Chunguang, assistant general manager of Tiger Pharma, said. transformation research is increasingly strong
as the latest frontier of medical research, translational medicine has received unprecedented attention Professor Yang Baofeng, President of Harbin Medical University, said that translational medicine, especially in the high-throughput screening of drugs and the discovery of disease prediction and diagnostic markers, by including basic research, clinical hospitals and other departments involved in the transformational medical research projects have great advantages, for the development of new drugs, early diagnosis of major diseases and other new research ideas, and make clinical diagnosis and treatment can benefit in the shortest time National centers for translational medicine have been gradually established, and China has established a number of translational medical research centers with the support of some universities and research institutes. , Dr Zhanxiang, General Representative of the China Representative Office of the Global Physicians Organization, said that at present, China has identified translational medicine as an important development direction in the frontier sewenewory field In the Medium- and Long-Term Plan for the National Major Science and Technology Infrastructure Construction (2012-2030), it is clear that one of the key points of construction during the 12th Five-Year Plan period is to build transformational medical research facilities around major scientific issues in the occurrence, development and return of major human diseases At present, more than 130 clinical and translational medicine centers have been set up in China The National Development and Reform Commission has established a project to support the construction intention of five national clinical and translational medical centers, such as Ruijin Hospital affiliated with Shanghai Jiaotong University, with the aim of establishing a national-level collaborative platform for translational medicine, promoting the effective transformation of China's biological and medical research achievements, and improving the level of diagnosis and treatment of diseases. Yang Baofeng, as an example, as the main base of translational medicine research in northeast China, Harbin Medical University North Translational Medical Research Cooperation Center under the diagnostic research and development, tissue engineering, biological function, molecular biology, cell engineering, new drug research and development and bio-information engineering 7 platforms, the working unit includes basic medicine, pharmacy, clinical research, one of the main research direction is for major, complex disease treatment technology transformation research For example, for the treatment of gastrointestinal tumors of peptide drug research and development, reveal the role of lncRNA, microRNA and other non-coding RNA in cardiovascular disease, the detection of related disease biomarkers, and the development of nucleic acid drugs, reveal the new role and application of stem cells in cardiovascular disease, and use gene modification and other techniques to improve the efficacy and safety of clinical stem cell transplantation, fat-lowering, sugar-lowering Chinese medicine research and development. July 18, this year, to "based on innovation, leading the standards of stem cell technology system; Zhao Chunhua, a researcher at the Institute of Basic Medicine of the Chinese Academy of Medical Sciences, said that in recent years, the western developed countries have been increasing support for the development of new stem cell drugs, and the world has approved the treatment of knee cartilage defects ChondroCelect (autonomous cartilage cells) and other 7 stem cell drugs on the market, and China is still blank in this field, as soon as possible to develop stem cell with China's independent intellectual property rights is imminent new drugs China should promote the development and application of stem cell translational medicine, build a multi-disciplinary cross-collaboration network from basic to clinical, and transform the results of basic research into a real treatment tool for patients.  Liu Chunguang, , said that during the "13th Five-Year Plan" period, China's innovative drugs should be supported and under the guidance of the government, and actively build a substantial cooperation platform for industry, research and development, collaborative innovation, collaborative efforts, focus on solving the constraints on the creation of new drug technology bottlenecks, human resources bottlenecks, capital bottlenecks, open up the upstream and downstream industrial chain of new drug research and development services, improve research and development efficiency and research and development quality, and promote the healthy and rapid development of China's pharmaceutical industry.